Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary/Respiratory Diseases Clear all
Active, not recruiting No phase listed Observational

Pulmonary Vascular Disease in CF

NCT04549077
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Indianapolis, Indiana • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Pneumocystis in COPD (the TOPIC Study)

NCT05418777
View directory record Official record
Conditions
COPD Exacerbation Acute
Interventions
Trimethoprim Sulfamethoxazole, Placebo
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
40 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD

NCT02097992
View directory record Official record
Conditions
COPD
Interventions
Roflumilast Placebo, Roflumilast
Drug
Lead sponsor
University of Miami
Other
Eligibility
45 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

NCT02412111
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Tezacaftor/Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Jul 23, 2026, 2:14 PM EDT
Active, not recruiting No phase listed Observational

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)

NCT05520099
View directory record Official record
Conditions
Immunotherapy, Cancer, Bladder Cancer, Urothelial Carcinoma Bladder, Kidney Cancer, Clear Cell Renal Cell Cancer (ccRCC), Colorectal Cancer, MSI-H Colorectal Cancer, DMMR Colorectal Cancer, Head and Neck Cancer (H&N), Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Liver Cancer, Hepatocellular Carcinoma (HCC), Lung Cancer (NSCLC), NSCLC (Non-small Cell Lung Cancer), Skin Cancer, Cutaneous Melanoma, Endometrial Cancer, Solid Tumor Cancer
Interventions
Core Needle Biopsy, Forceps Biopsy, Punch Biopsy
Procedure
Lead sponsor
Elephas
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

NCT03790332
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
1 Year to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Duarte, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions

NCT01659931
View directory record Official record
Conditions
Asthma
Interventions
Montelukast, Singulair
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

NCT03451045
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lenabasum 20 mg, Lenabasum 5 mg, Placebo
Drug · Other
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Jul 23, 2026, 2:14 PM EDT
Terminated Phase 4 Interventional Results available

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

NCT02275481
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Arformoterol tartrate inhalation solution, Tiotropium
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
55 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 23, 2026, 2:14 PM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib and Rituxan for Chronic GVHD

NCT04235036
View directory record Official record
Conditions
Graft Vs Host Disease
Interventions
Rituximab, Ibrutinib
Drug
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence

NCT01175434
View directory record Official record
Conditions
Asthma
Interventions
School-Based Medication Delivery
Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 10 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Jul 23, 2026, 2:14 PM EDT
Terminated Phase 1 Interventional

Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer

NCT00268151
View directory record Official record
Conditions
Carcinoma, Non-Small Cell Lung
Interventions
Oxaliplatin, Capecitabine
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Jul 23, 2026, 2:14 PM EDT
Completed No phase listed Observational

The Effect of Obesity on Lung Functioning

NCT00284895
View directory record Official record
Conditions
Obesity, Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 1 Interventional

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972
View directory record Official record
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia

NCT04341675
View directory record Official record
Conditions
COVID-19
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 23, 2026, 2:14 PM EDT
Active, not recruiting Phase 3 Interventional

Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer

NCT05132075
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
JDQ443, docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

NCT06855771
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BMS-986504
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Anchorage, Alaska • Boise, Idaho • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Not applicable Interventional Results available

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

NCT04798664
View directory record Official record
Conditions
Smoking Cessation
Interventions
Removal of Financial Barriers, Financial Incentives, Mobile Health Application
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Oakland, California • Detroit, Michigan • Danville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

NCT07030257
View directory record Official record
Conditions
Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC ), Head and Neck (HNSCC), Bladder Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Advanced or Metastatic
Interventions
CP-383
Drug
Lead sponsor
Tasca Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
13
States / cities
Denver, Colorado • Orlando, Florida • Grand Rapids, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

NCT06732401
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Echocardiography Test
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
193
States / cities
Jonesboro, Arkansas • Beverly Hills, California • Los Angeles, California + 164 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 23, 2026, 2:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

NCT05241834
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Interventions
LOXO-260
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 23, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01366209
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 23, 2026, 2:14 PM EDT